Portage Provides Default Status Report
Portage Biotech Inc. (PBT.U, OTC Markets: PTGEF) (“Portage” or the “Company”) is providing an update on the status of the filing of its audited annual financial statements for the year ended March 31, 2019, accompanying management discussion and analysis together with the related certifications (collectively, the “Annual Filings”).
The Annual Filings have been completed but are currently being reviewed for quality assurance by the Company’s auditors. The Company anticipates that final approval and posting of the Annual Filings on www.sedar.com will be completed shortly.
As a consequence of the delay in the preparation of the Annual Filings, the Company also announces that the filing of its financial statements for the three-month period ended June 30, 2019, accompanying management discussion and analysis together with the related certifications (the “Interim Filings”) will also be delayed and not released as required on August 29, 2019. The Company expects the Interim Filings to be filed shortly after the Annual Filings are filed.
On August 2, 2019, the Ontario Securities Commission (the “OSC”) issued a Failure-to-File Cease Trade Order against the Company on (the “FFCTO”) as a result of the Company’s failure to the Annual Filings by the prescribed filing deadline of July 29, 2019, as required by National Instrument 51-102, Continuous Disclosure Obligations, and NI 52-109, Certification of Disclosure in Issuers’ Annual and Interim Filings, respectively. The FFCTO remains in place.
The Company reports that since its news release of July 31, 2019, there have been no material changes regarding the information contained in that news release. Further, there is no other material information concerning the affairs of the Company that has not been generally disclosed.